The American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA presented exciting results from the ASPIRE trial (NCT01080391) for relapsed multiple myeloma (MM), testing the addition of the proteasome inhibitor carfilzomib to lenalidomide and dexamethasone therapy. Speaking from the meeting, Greg Friberg, MD, of Amgen Inc., Thousand Oaks, CA, discusses the positive follow-up data presented on patient outcomes.
Results of the ASPIRE trial for MM: the addition of carfilzomib
